Johanna Weiss

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi request reprint Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors
    Johanna Weiss
    AIDS 16:674-6. 2002
  2. ncbi request reprint Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2)
    Heike Lindenmaier
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Drug Metab Dispos 33:1576-9. 2005
  3. ncbi request reprint Interaction of antiepileptic drugs with human P-glycoprotein in vitro
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Germany
    J Pharmacol Exp Ther 307:262-7. 2003
  4. ncbi request reprint Rapid detection of polymorphisms of the nitric oxide cascade
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Germany
    Clin Chem Lab Med 40:341-4. 2002
  5. ncbi request reprint Inhibition of P-glycoprotein by newer antidepressants
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology, and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    J Pharmacol Exp Ther 305:197-204. 2003
  6. ncbi request reprint Rapid and reliable genotyping of the C181T polymorphism in the bradykinin B2 receptor gene
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Clin Chem Lab Med 41:281-3. 2003
  7. ncbi request reprint Quantification of mRNA levels with reverse transcription-polymerase chain reaction
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Bergheimer Strasse 58, D 69115, Heidelberg, Germany
    Biochem Biophys Res Commun 311:561-2. 2003
  8. doi request reprint CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    J Clin Pharmacol 49:196-204. 2009
  9. pmc Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation
    Ruth Fricker
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, D 69120 Heidelberg, Germany
    Br J Clin Pharmacol 58:169-77. 2004
  10. ncbi request reprint Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
    Gerd Mikus
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Clin Pharmacol Ther 80:126-35. 2006

Collaborators

Detail Information

Publications73

  1. ncbi request reprint Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors
    Johanna Weiss
    AIDS 16:674-6. 2002
  2. ncbi request reprint Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2)
    Heike Lindenmaier
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Drug Metab Dispos 33:1576-9. 2005
    ..In conclusion, the progestins norgestimate and progesterone significantly inhibit the transport activity of MRP2 in vitro...
  3. ncbi request reprint Interaction of antiepileptic drugs with human P-glycoprotein in vitro
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Germany
    J Pharmacol Exp Ther 307:262-7. 2003
    ..However, it is possible that this inhibition may contribute to the effectiveness of certain add-on therapies...
  4. ncbi request reprint Rapid detection of polymorphisms of the nitric oxide cascade
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Germany
    Clin Chem Lab Med 40:341-4. 2002
    ..The new methods are more reliable, faster and less expensive than PCR-RFLP analysis and therefore represent a significant advantage in the detection of two candidate risk factors for cardiovascular diseases...
  5. ncbi request reprint Inhibition of P-glycoprotein by newer antidepressants
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology, and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    J Pharmacol Exp Ther 305:197-204. 2003
    ....
  6. ncbi request reprint Rapid and reliable genotyping of the C181T polymorphism in the bradykinin B2 receptor gene
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Clin Chem Lab Med 41:281-3. 2003
    ..It allows the solid evaluation of large patient populations with the best time...
  7. ncbi request reprint Quantification of mRNA levels with reverse transcription-polymerase chain reaction
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Bergheimer Strasse 58, D 69115, Heidelberg, Germany
    Biochem Biophys Res Commun 311:561-2. 2003
  8. doi request reprint CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    J Clin Pharmacol 49:196-204. 2009
    ..Some minor contribution results from the MDR1 C3435T genotype...
  9. pmc Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation
    Ruth Fricker
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, D 69120 Heidelberg, Germany
    Br J Clin Pharmacol 58:169-77. 2004
    ....
  10. ncbi request reprint Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
    Gerd Mikus
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Clin Pharmacol Ther 80:126-35. 2006
    ..This study thus assessed the effect of the potent CYP3A4 inhibitor ritonavir after short-term administration on voriconazole pharmacokinetics in extensive metabolizers (EMs) and poor metabolizers (PMs) of CYP2C19...
  11. doi request reprint Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1
    Christoph Markert
    Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital of Heidelberg, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
    Eur J Clin Pharmacol 69:1785-93. 2013
    ..We assessed the effect of cytochrome P450 (CYP) 3A4 and the OATP1B1 inhibitor clarithromycin on ambrisentan steady-state kinetics and its relationship to the SLCO1B1 15 haplotype in healthy volunteers...
  12. pmc Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
    Ina Scholz
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Br J Clin Pharmacol 68:906-15. 2009
    ..Oral bioavailability of voriconazole has been claimed to be almost 100%, thus facilitating a change from intravenous to oral application without dose adjustment...
  13. doi request reprint Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity
    Ines Fuchs
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Eur J Clin Pharmacol 69:507-13. 2013
    ..The aim of this clinical study was to investigate a previously proposed mechanism of ketoconazole-mediated inhibition of cytochrome P450 3A (CYP3A) induction...
  14. doi request reprint Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity
    Melanie Herzog
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Naunyn Schmiedebergs Arch Pharmacol 383:1-11. 2011
    ..The diminished BCRP function after Cav1 knockdown is, thus, likely mediated by alterations in protein-protein interactions and suggests a positive regulation of BCRP function by CAV1...
  15. doi request reprint Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro
    Juan Pablo Rigalli
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Cancer Chemother Pharmacol 71:1335-43. 2013
    ..The aim of this work was to establish the relevance of PXR for MDR in head and neck squamous cell carcinoma (HNSCC)...
  16. doi request reprint Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells
    Johanna Weiss
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Biochem Pharmacol 85:265-73. 2013
    ....
  17. ncbi request reprint Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers
    Reinhard Ding
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Germany
    Clin Pharmacol Ther 76:73-84. 2004
    ..This study assessed the effect of repetitive ritonavir administration on digoxin distribution and total and renal digoxin clearance as a marker for P-gp activity in vivo...
  18. ncbi request reprint Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics
    Jens Rengelshausen
    Department of Internal Medicine VI, Clinial Pharmacology and Pharmacoepidemiology, University of Heidelberg, D 69120 Heidelberg, Germany
    Clin Pharmacol Ther 78:25-33. 2005
    ..This study investigates both short- and long-term effects of SJW on the antifungal voriconazole, which is metabolized by these enzymes...
  19. ncbi request reprint Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction
    Gerd Mikus
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Clin Pharmacokinet 43:1015-24. 2004
    ..To assess any pharmacokinetic interactions between loperamide and saquinavir...
  20. ncbi request reprint Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Eur J Pharmacol 579:104-9. 2008
    ..P-glycoprotein activity was increased by all NNRTIs and some NRTIs with delavirdine (5.3-fold at 100 muM) having the largest effect...
  21. ncbi request reprint Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein
    Caroline Henrike Storch
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany
    Biochem Pharmacol 73:1573-81. 2007
    ....
  22. ncbi request reprint Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro
    Caroline Henrike Storch
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    J Pharmacol Exp Ther 323:257-64. 2007
    ..In conclusion, our results demonstrate for the first time that BCRP is located in membrane rafts and that cholesterol has impact on its efflux activity...
  23. ncbi request reprint P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine
    Nahal Ketabi-Kiyanvash
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University Hospital, Bergheimer Strasse 58, D 69115 Heidelberg, Germany
    Addict Biol 8:413-8. 2003
    ..However, it cannot be excluded that co-administration of Pgp inhibitors such as ritonavir or paroxetine could increase MDMA, MDE and PMA bioavailability and also enhance brain entry leading to severe side effects...
  24. ncbi request reprint Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells
    Caroline Henrike Storch
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Naunyn Schmiedebergs Arch Pharmacol 376:135-43. 2007
    ..These results need further confirmation because investigation of age dependency of P-gp activity was not the primary aim of the study...
  25. pmc Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction
    Jens Rengelshausen
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Br J Clin Pharmacol 56:32-8. 2003
    ..The aim of this study was to investigate the extent of the interaction and the relative contribution of different mechanisms...
  26. ncbi request reprint Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy
    Dirk Theile
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Biochem Pharmacol 78:1366-73. 2009
    ..In conclusion, we propose as one mechanism for FOLFOX synergism the 5-FU mediated suppression of ATP7B, the over-expression of glutathione exporters such as MRP2/ABCC2 and the decrease of glutathione levels by oxalate...
  27. doi request reprint Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring
    Arwa Hassan
    Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany
    Ther Drug Monit 33:86-93. 2011
    ..In the remaining patients, ultrarapid metabolism resulting from the CYP2C19*17 polymorphism appears to play a major role. Thus, in the case of voriconazole therapy failure, both nonadherence and genetic factors have to be considered...
  28. ncbi request reprint Modulation of human BCRP (ABCG2) activity by anti-HIV drugs
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    J Antimicrob Chemother 59:238-45. 2007
    ..The aim of this study was therefore to investigate the influence of all important anti-HIV drugs on BCRP activity in vitro in one assay to allow unrestricted comparison of the results...
  29. pmc Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters
    Barbara Grun
    Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, 69120, Heidelberg, Germany
    Br J Clin Pharmacol 76:787-96. 2013
    ..The aim of this study was to investigate the effects of trimethoprim on metformin pharmacokinetics and genetic modulation by organic cation transporter 2 (OCT2) and multidrug and toxin extrusion 1 (MATE1) polymorphisms...
  30. doi request reprint Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma
    Dirk Theile
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Head Neck 33:959-68. 2011
    ..Multidrug resistance (MDR) hampers chemotherapy in head and neck squamous cell carcinoma (HNSCC). There is little information about MDR mediating drug transporters in HNSCC...
  31. ncbi request reprint Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein
    Tanja Peters
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120, Heidelberg, Germany
    Naunyn Schmiedebergs Arch Pharmacol 372:291-9. 2006
    ..The observed interaction profile of monastrol with Pgp is promising for the development of other more potent Eg5 inhibitors...
  32. ncbi request reprint Expression and activity of P-glycoprotein (MDR1/ABCB1) in peripheral blood mononuclear cells from patients with anorexia nervosa compared with healthy controls
    Caroline Henrike Storch
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, D 69120 Heidelberg, Germany
    Int J Eat Disord 41:432-8. 2008
    ..The aim of our study was to investigate expression and activity levels of P-gp in peripheral blood mononuclear cells (PBMCs) in AN patients...
  33. ncbi request reprint NKIM-6, a new immortalized human brain capillary endothelial cell line with conserved endothelial characteristics
    Nahal Ketabi-Kiyanvash
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Cell Tissue Res 328:19-29. 2007
    ..Our results suggest that this cell line might be suitable as in vitro model for several aspects of the BBB...
  34. ncbi request reprint Lack of evidence for association of high altitude pulmonary edema and polymorphisms of the NO pathway
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Bergheimer Strasse 58, D 69115 Heidelberg, Germany
    High Alt Med Biol 4:355-66. 2003
    ..The results of this study suggest that none of these genetic variants plays a substantial role in the pathogenesis of HAPE in Caucasians, but does not exclude epistatic effects that might still involve the genetic systems studied here...
  35. ncbi request reprint In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Naunyn Schmiedebergs Arch Pharmacol 378:275-82. 2008
    ..In vivo, drug-drug interactions of tilidine with CYP3A4 or CYP2C19 inhibitors are to be anticipated, whereas substrates of CYP2C19, ABCB1, or ABCG2 will presumably not be influenced by tilidine or nortilidine...
  36. doi request reprint Daily honey consumption does not change CYP3A activity in humans
    Leonie Fetzner
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    J Clin Pharmacol 51:1223-32. 2011
    ..Neither honey nor artificial honey in amounts usually consumed affected the intestinal and hepatic CYP3A activity in healthy volunteers...
  37. ncbi request reprint Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity
    Felicitas Stoll
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, 69120, Heidelberg, Germany
    J Clin Pharmacol 53:1199-204. 2013
    ..2 [90% CI: 3.15-5.61]) probably caused by additional OATP1B1 inhibition. CYP3A activity-based dose adaptation can be used to reduce interindividual variability in simvastatin exposure. ..
  38. doi request reprint Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings
    Victoria C Ziesenitz
    Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany
    Basic Clin Pharmacol Toxicol 113:43-8. 2013
    ..5). In addition, in vitro data also indicate that fentanyl is not transported by OATP1B1. In conclusion, our data indicate that OATP1B1 has no impact on fentanyl pharmacokinetics in human beings...
  39. doi request reprint Impact of drug transporters on cellular resistance towards saquinavir and darunavir
    Sonja Katharina König
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    J Antimicrob Chemother 65:2319-28. 2010
    ..We therefore investigated the effect of saquinavir and darunavir on drug transporter expression and functional consequences for cellular resistance towards these compounds...
  40. ncbi request reprint Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells
    Joachim Troost
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Mol Pharmacol 66:1332-9. 2004
    ..These results demonstrate that cholesterol alterations influence P-glycoprotein localization and function, which might contribute to the large interindividual variability of P-glycoprotein activity known from in vivo studies...
  41. ncbi request reprint Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, DE 69120 Heidelberg, Germany
    Pharmacology 84:264-70. 2009
    ....
  42. ncbi request reprint Induction of multiple drug transporters by efavirenz
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Germany
    J Pharmacol Sci 109:242-50. 2009
    ..While these expressional changes will most likely not influence the efficiency of efavirenz itself, they might change the effect of other co-administered drugs...
  43. ncbi request reprint In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins
    Margit Fröhlich
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Biochem Pharmacol 68:2409-16. 2004
    ..The results may be of particular importance for Pgp substrates, such as protease inhibitors and chemotherapeutic agents, for which intracellular concentrations are critical...
  44. pmc Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine
    Barbara Grun
    Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, Heidelberg, Germany
    Br J Clin Pharmacol 74:854-63. 2012
    ..The novel CYP2C19 gene variant CYP2C19*17 causes ultrarapid drug metabolism, in contrast to the *2 and *3 variants, which result in impaired drug metabolism...
  45. pmc No difference in genotype frequencies of polymorphisms of the nitric oxide pathway between Caucasian normal and high tension glaucoma patients
    Johanna Weiss
    Department of Clinical Pharmacology and Pharmacoepidemiology University of Heidelberg, Heidelberg, Germany
    Mol Vis 18:2174-81. 2012
    ..We also compared the distribution of these polymorphisms in patients with high tension glaucoma (HTG) and normal tension glaucoma (NTG) and evaluated its association with vascular dysregulation in a subset of glaucoma patients...
  46. pmc Oral contraception does not alter single dose saquinavir pharmacokinetics in women
    Margit Fröhlich
    Department of Internal Medicine VI, University Women s Hospital, University of Heidelberg, Germany
    Br J Clin Pharmacol 57:244-52. 2004
    ..Thus, in the present study we aimed to investigate the influence of oral contraceptives (OC) on the pharmacokinetics of the protease inhibitor saquinavir...
  47. doi request reprint Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro
    Johanna Weiss
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
    Cancer Chemother Pharmacol 68:1093-8. 2011
    ....
  48. ncbi request reprint Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Drug Metab Dispos 35:340-4. 2007
    ....
  49. pmc No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment
    Jürgen Burhenne
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Antimicrob Agents Chemother 54:4185-91. 2010
    ....
  50. ncbi request reprint Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver
    Nadine Albermann
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Biochem Pharmacol 70:949-58. 2005
    ..However, the transporter status in PBMCs remains important for drugs, whose primary site of therapeutic action is the lymphocyte and which are known substrates of the transporters...
  51. pmc Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers
    Christoph Markert
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Br J Clin Pharmacol 77:141-8. 2014
    ..We also aimed to evaluate the impact of CYP2C9 and SLCO1B1 (encoding for OATP1B1) genotypes and their combination...
  52. doi request reprint Liposomal sphingomyelin influences the cellular lipid profile of human lymphoblastic leukemia cells without effect on P-glycoprotein activity
    Nadine C L Zembruski
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Mol Pharm 10:1020-34. 2013
    ..SM-only liposomes did not influence P-gp activity and chemosensitivity. In conclusion, SM-only liposomes in therapeutic amounts did not influence P-gp mediated multidrug resistance in CEM cells...
  53. doi request reprint Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro
    Johanna Weiss
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Eur J Pharmacol 701:168-75. 2013
    ....
  54. doi request reprint Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro
    Anja Keubler
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Drug Metab Dispos 40:1178-82. 2012
    ..The increase in 1'-hydroxymidazolam formation may have been caused by binding of efavirenz to a peripheral site of the enzyme, leading to enhanced midazolam turnover due to changes at the active site...
  55. ncbi request reprint Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Drug Metab Dispos 33:1580-3. 2005
    ..The f2 value of yangonin could not be determined due to its higher lipophilicity. In conclusion, our results for the first time demonstrate P-gp-inhibitory activity of kava-kava and its components in vitro...
  56. ncbi request reprint Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values
    Johanna Weiss
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Drug Metab Dispos 34:203-7. 2006
    ..Although it was only tested for inhibition of P-glycoprotein, it seems likely that this method may be transferred to other assays with other proteins...
  57. doi request reprint Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro
    Johanna Weiss
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Eur J Pharmacol 660:298-304. 2011
    ..9-fold for bosentan). In contrast, ambrisentan only weakly induced some of the genes investigated in LS180 cells. These findings corroborate the in vivo finding that bosentan is much more prone to drug interactions than ambrisentan...
  58. doi request reprint Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease
    Dirk Theile
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Alcohol Clin Exp Res 37:E17-22. 2013
    ....
  59. doi request reprint Cellular pharmacokinetic/pharmacodynamic relationship of platinum cytostatics in head and neck squamous cell carcinoma evaluated by liquid chromatography coupled to tandem mass spectrometry
    Dirk Theile
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    J Pharmacol Exp Ther 341:51-8. 2012
    ....
  60. ncbi request reprint Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine
    Jens Rengelshausen
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Biochem Biophys Res Commun 320:90-4. 2004
    ..The central involvement of hOAT1 in the renal excretion of numerous drugs suggests that this inhibition may alter the pharmacokinetics of a series of clinically important drugs in humans...
  61. ncbi request reprint Factors determining sensitivity or resistance of tumor cell lines towards artesunate
    Serkan Sertel
    Department of Otorhinolaryngology, Head and Neck Surgery, University of Heidelberg, Heidelberg, Germany
    Chem Biol Interact 185:42-52. 2010
    ..It merits further investigation, whether ART is responsive in clinically refractory tumors and whether the genes identified in the present study also determine clinical responsiveness towards ART...
  62. ncbi request reprint Influence of lipid lowering fibrates on P-glycoprotein activity in vitro
    Manuela Ehrhardt
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Bergheimer Strasse 58, D 69115, Heidelberg, Germany
    Biochem Pharmacol 67:285-92. 2004
    ..In conclusion, this study demonstrates that fenofibrate inhibits Pgp in vitro with a potency similar to simvastatin...
  63. doi request reprint Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy
    Johanna Weiss
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
    Int Rev Cell Mol Biol 280:219-79. 2010
    ..Moreover, the suitability of different cell models for studying the interaction of antiretrovirals with ABC-transporters is discussed...
  64. ncbi request reprint 7-Aminoactinomycin D for apoptosis staining in flow cytometry
    Nadine C L Zembruski
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, 69120 Heidelberg, Germany
    Anal Biochem 429:79-81. 2012
    ..The results showed that 7-AAD staining with 5, 10, and 20μg/ml, but not with 1μg/ml, is suitable for quantification of apoptosis in flow cytometry...
  65. ncbi request reprint Rifampicin alters the expression of reference genes used to normalize real-time quantitative RT-PCR data
    Johanna Weiss
    Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
    Naunyn Schmiedebergs Arch Pharmacol 385:1025-34. 2012
    ..Scrutiny of the reference gene expression and plausibility of the data remain necessary and protect from erroneous quantification and misinterpretation of qRT-PCR data...
  66. doi request reprint In vitro identification of the cytochrome P450 isozymes involved in the N-demethylation of the active opioid metabolite nortilidine to bisnortilidine
    Isabel Wustrow
    Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany
    Naunyn Schmiedebergs Arch Pharmacol 385:633-9. 2012
    ..Pharmacokinetic interactions can be expected with inhibitors or inducers of CYP3A4, CYP2C19 or CYP2B6...
  67. pmc Interaction potential of etravirine with drug transporters assessed in vitro
    Nadine Cécile Luise Zembruski
    Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Antimicrob Agents Chemother 55:1282-4. 2011
    ..Etravirine induced several ABC transporters, especially BCRP/ABCG2. These data demonstrate that etravirine has the potential for drug-drug interactions by modulation of expression and function of several ABC transporters...
  68. ncbi request reprint Reduction of cytotoxicity of the alkaloid emetine through P-glycoprotein (MDR1/ABCB1) in human Caco-2 cells and leukemia cell lines
    Maren Möller
    Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg, Germany
    Planta Med 72:1121-6. 2006
    ..17 microM for Jurkat cells). Apparently emetine is a substrate for MDR1 but not for MRP1. Furthermore, emetine is able to up-regulate the expression of MDR1 as shown IN VITRO by real-time PCR and transport activity studies...
  69. ncbi request reprint Cholesterol modulates P-glycoprotein activity in human peripheral blood mononuclear cells
    Joachim Troost
    Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Bergheimer Str 58, D 69115 Heidelberg, Germany
    Biochem Biophys Res Commun 316:705-11. 2004
    ..4%+/-1.6 (p<0.001) in lymphocytes and 12.9%+/-3.5 (p<0.001) in monocytes. These data demonstrate that elevated cellular cholesterol levels can markedly increase P-gp activity in human PBMCs...
  70. pmc Regulation of biotransformation systems and ABC transporters by benznidazole in HepG2 cells: involvement of pregnane X-receptor
    Juan P Rigalli
    Institute of Experimental Physiology, School of Biochemical and Pharmaceutical Sciences, Rosario, Argentina
    PLoS Negl Trop Dis 6:e1951. 2012
    ..Benznidazole (BZL) is the only antichagasic drug available in most endemic countries. Its effect on the expression and activity of drug-metabolizing and transporter proteins has not been studied yet...
  71. ncbi request reprint Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40
    Yorki Tayrouz
    Department of Internal Medicine, University of Heidelberg, Germany
    Clin Pharmacol Ther 73:397-405. 2003
    ..So far, no study in humans has evaluated the effect of Cremophor RH40 (BASF Aktiengesellschaft) (polyoxyl 40 hydrogenated castor oil) on P-glycoprotein...
  72. pmc Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics
    Margit Fröhlich
    Br J Clin Pharmacol 58:443-4. 2004
  73. pmc Genotyping of the A6986G polymorphism of CYP3A5
    Johanna Weiss
    Br J Clin Pharmacol 57:663; author reply 664. 2004